Clinical trial

Immunotherapy
#Cancer immunotherapy #Clinical trial #Melanoma

Immunotherapy before surgery could better treat melanoma 

Administering immunotherapy to melanoma patients before surgery could shrink tumours and improve quality of life.  New research, published in Nature Cancer, shows that 71% of desmoplastic melanoma patients who received the immunotherapy drug pembrolizumab before surgery had no detectable cancer remaining at the time of surgery.   Administering… Read More

#Cancer Research #News

Overweight man clutching his knee
#Clinical trial #Obesity

New obesity drug may cause fewer side effects, results show 

A new obesity treatment which could cause fewer side effects has demonstrated a strong pharmacokinetic (PK) profile in preclinical trial.  The treatment, developed by pharmaceutical company Nanexa AB, reportedly indicated a very low ratio between the maximum and minimum plasma concentration over the dosing interval following once-monthly subcutaneous administration.  The company’s… Read More

#News

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

DDW Highlights: 27 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an innovative therapy showed encouraging results in tackling melanoma. Elsewhere, why is… Read More

#Podcasts

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

This week in Drug Discovery (19 – 23 January) 

News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology.  The top stories:    Combination therapy could slash melanoma mortality… Read More

#News

#AI #Clinical trial #Drug discovery #Parse Biosciences

Life science partnership to improve AI-driven drug discovery  

Life sciences company Parse Biosciences has partnered with research institute Graph Therapeutics to create what it says is one of the largest and most comprehensive immune cell perturbation atlases.  The collaboration will leverage Graph's lab-in-the-loop platform with Parse's GigLab to profile hundreds of millions of cells from patients with immune diseases under systematic perturbation, making the… Read More

#Business & Investment #News

Non-small cell lung cancer
#Clinical trial #Gut microbiome #Non-small cell lung cancer (NSCLC)

First patient randomised in NSCLC Phase II trial 

The first patient has been randomised in a Phase II trial evaluating an oral microbiome therapy in combination with Cemiplimab to treat patients with advanced non-small cell lung cancer (NSCLC).  Maat033, an oral microbiome developed by biotechnology company MaaT Pharma, is being studied as a treatment in combination with Cemiplimab in enhancing disease… Read More

#News

Melanoma or skin cancer
#Clinical trial #Melanoma #Merck #Moderna

Combination therapy could slash melanoma mortality risk 

Merck and Moderna have announced encouraging five-year data for a therapy treating patients with high-risk melanoma.  The Phase IIb trial of intismeran autogene, an investigational mRNA-based individualised neoantigen therapy (INT), reduced the risk of high-risk melanoma recurrence or death by 49% when combined with Keytruda (pembrolizumab).  The combination… Read More

#News

Concussion brain scan
#Clinical trial #Concussion #Oxeia Biopharmaceuticals

Oxeia advances potential first FDA-approved concussion drug 

Biotech Oxeia Biopharmaceuticals is advancing a potential first FDA-approved concussion treatment into Phase IIb clinical testing.  OXE103, a therapy for persistent concussion symptoms, demonstrated an 85% responder rate in Phase IIa clinical testing and will be evaluated in Phase IIb trial.  Between 1.4 and 4.2 million people… Read More

#News

Bristol Myers Squibb offices
#Bristol Myers Squibb #Clinical trial #Drug discovery

Bristol Myers Squibb extends Syngene partnership 

Bristol Myers Squibb has extended its long-term research collaboration with global CRDMO Syngene until 2035.  The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery, translational sciences, pharmaceutical development and manufacturing, clinical trials, data, and information technology services, to enable seamless progression from research to commercialisation.   “At… Read More

#Business & Investment #News

Medical laboratory
#Clinical trial #Dermatology #JP Morgan Healthcare Conference

Almirall to initiate three clinical trials in dermatology field 

Global pharmaceutical company Almirall has announced it will launch three clinical trials in 2026 to further advances in the medical dermatology field.  Speaking at the 44th J.P. Morgan Healthcare Conference, which took place in San Francisco, Almirall CEO Carlos Gallardo said the company was focused on developing impactful novel… Read More

#News

Pancreatic cancer
#Clinical trial #Pancreatic cancer

HUTCHMED begins Phase III trial of PDAC treatment 

Biopharmaceutical company HUTCHMED has launched the Phase III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC).  PDAC is a highly aggressive form of cancer, representing over 90% of pancreatic cancer cases. Globally, an estimated 511,000 people were diagnosed… Read More

#Cancer Research #News

Laboratory research
#Antag Therapeutics #Clinical trial #Obesity

Novel obesity drug could be ‘combination partner of choice’ 

Biotechnology company Antag Therapeutics has revealed promising results from its novel GIPR antagonist for the treatment of obesity.  AT7687, a first-in-class GIPR antagonist, was trialled in a Phase I randomised, double-blind, placebo-controlled study. Results show AT7687 demonstrated a favourable safety and tolerability profile across all doses.  The… Read More

#News

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

DDW Highlights: 13 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a new report found breast cancer was the world’s most studied disease… Read More

#Podcasts

Monoclonal antibody
#Acute inflammatory conditions #Autoimmune disease #Clinical trial #Monoclonal antibodies

Nucleome to develop first-in-class monoclonal antibody 

Biotechnology company Nucleome Therapeutics is set to advance a potential first-in-class treatment for major chronic inflammatory diseases.  NTP464 is a potential first-in-class monoclonal antibody agonist with strong potency, selectivity and developability characteristics. Nucleome has nominated NTP646 for development.  The target of NTP464 is a novel inflammation checkpoint identified using Nucleome’s proprietary suite of… Read More

#News

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

This week in Drug Discovery (5 – 9 January) 

News round-up for 5 – 9 January by Bruno Quinney, Content Team at DDW.  This week in DDW, a new report finds breast cancer is the world’s most studied disease for the fifth year running. That same report predicts obesity to break into the top five, with weight loss a key theme across… Read More

#News

CAR-T cell therapy
#Advanced Therapies #CAR-T #Clinical trial #Financing

Vyriad raises $85m to advance CAR-T candidate to clinic 

Biotechnology company Vyriad has closed the final $25 million tranche of its Series B financing round to advance the company’s in vivo CAR-T candidate to clinic.  VV169 has been developed by Vyriad for the treatment of patients with relapsed or treatment-refractory multiple myeloma. The treatment is one of the first in vivo CAR-T candidates leveraging Vyriad’s lentiviral platform, combining an… Read More

#Business & Investment #News